Universität zu Köln

Wierda, William G., Kipps, Thomas J., Al-Sawaf, Othman, Chyla, Brenda, Biondo, Juliana M. L., Mun, Yong, Jiang, Yanwen and Seymour, John F. (2022). Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk. Lymphoma, 63 (12). S. 2765 - 2785. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

Inhibitors targeting B-cell receptor (BCR) signaling pathway proteins and B-cell lymphoma-2 (BCL2) in chronic lymphocytic leukemia (CLL) are recommended in the first-line and relapsed/refractory disease settings. Measurable residual disease (MRD) is an important prognostic tool in patients treated with the BCL2-targeted agent, venetoclax. We explored the relationship between MRD status and progression-free (PFS)/overall survival (OS) in patients with CLL, following treatment with novel BCR- and BCL2-targeted agents. Compared with chemoimmunotherapy, higher rates of undetectable (u)MRD were achieved with BCL2-targeted therapies; achieving uMRD status was associated with longer PFS and OS than MRD-positivity. Continuous treatment with BCR-targeted agents did not achieve uMRD status in many patients, and outcomes were not correlated with uMRD status. Future clinical trials of targeted treatment combinations could be designed to demonstrate uMRD as a treatment objective, and allow a response-driven, personalized strategy to optimize treatment and improve OS outcomes.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wierda, William G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kipps, Thomas J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Al-Sawaf, Othman UNSPECIFIED UNSPECIFIED UNSPECIFIED Chyla, Brenda UNSPECIFIED UNSPECIFIED UNSPECIFIED Biondo, Juliana M. L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mun, Yong UNSPECIFIED UNSPECIFIED UNSPECIFIED Jiang, Yanwen UNSPECIFIED UNSPECIFIED UNSPECIFIED Seymour, John F. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-689223
DOI:	10.1080/10428194.2022.2098291
Journal or Publication Title:	Leuk. Lymphoma
Volume:	63
Number:	12
Page Range:	S. 2765 - 2785
Date:	2022
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1029-2403
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY UNTREATED PATIENTS; IBRUTINIB PLUS VENETOCLAX; 5-YEAR FOLLOW-UP; PHASE-II TRIAL; OPEN-LABEL; PROGRESSION-FREE; 1ST-LINE TREATMENT; END-POINT; RITUXIMAB Multiple languages Oncology; Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68922